Details for Patent: 8,282,966

« Back to Dashboard

Which drugs does patent 8,282,966 protect, and when does it expire?

Patent 8,282,966 protects INOMAX and is included in one NDA.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-five patent family members in six countries.

Summary for Patent: 8,282,966

Title:	Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide
Abstract:	The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.
Inventor(s):	James S. Baldassarre, Ralf Rosskamp
Assignee:	Mallinckrodt Pharma IP Trading DAC , Therakos Inc , Mallinckrodt Critical Care Finance Inc
Application Number:	US12/821,020
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,282,966
Patent Claim Types: see list of patent claims	Use; Process;

Drugs Protected by US Patent 8,282,966

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No					Y
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes					Y

International Family Members for US Patent 8,282,966

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009202685
Australia	2010202422
Australia	2010206032